Vaxcyte, Inc. PCVX · Stock Open Vaxcyte, Inc. in new tab
Vaxcyte, Inc. Analysis (PCVX)
Is Vaxcyte, Inc. a good investment? Vaxcyte, Inc. (PCVX) is currently trading at 58.92 USD. Market analysts have a consensus price target of 109.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Vaxcyte, Inc. is expected to release its next earnings report on Nov. 3, 2026. The market consensus estimate for Forward EPS is -7.22.
Investor FAQ
Does Vaxcyte, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Vaxcyte, Inc.?
Vaxcyte, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 3, 2026. The company currently has a trailing EPS of -7.84.
Company Profile
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Community Discussion